Drug Profile
Research programme: cancer therapeutics - Inception 2
Latest Information Update: 28 Jul 2016
Price :
$50
*
At a glance
- Originator Inception 2
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase Unknown Cancer
Most Recent Events
- 28 Jul 2016 Investigation in Cancer in Canada (unspecified route)
- 28 Jul 2016 Investigation in Cancer in USA (unspecified route)